Abstract: This technology relates in part to compositions and kits comprising nucleic acids, vectors, and cells that express HLA-J, as well as HLA-J proteins and peptides, and uses thereof, for example for medical treatments, vaccines and diagnosis.

Abstract: The present invention relates to a nucleic acid molecule, a vector, a host cell, or a protein or peptide, or any combination thereof for use in a method of increasing efficiency of embryonic implantation in an in vitro fertilization programme, (I) wherein the at least one nucleic acid molecule is selected from nucleic acid molecules (a) encoding a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs 1 to 17, (b) comprising or consisting of the nucleotide sequence of any one of SEQ ID NOs 18 to 23, (c) encoding a polypeptide which is at least 85% identical, preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of (a), (d) consisting of a nucleotide sequence which is at least 95% identical, preferably at least 96% identical, and most preferred at least 98% identical to the nucleotide sequence of (b), (e) consisting of a nucleotide sequence which is degenerate with respect to the nucleic acid molecule of (d), (f) consisting of

Abstract: The present invention relates to a method for producing a medicament for the treatment or prevention of a tumor in a subject or a diagnostic agent for the detection of a tumor in a subject comprising (A) determining the expression of at least one nucleic acid molecule and/or at least one protein or peptide in a sample obtained from said subject, wherein the at least one nucleic acid molecule is selected from nucleic acid molecules (a) encoding a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs 1 to 5, (b) comprising or consisting of the nucleotide sequence of any one of SEQ ID NOs 6 to 10, (c) encoding a polypeptide which is at least 85% identical, preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of (a), (d) consisting of a nucleotide sequence which is at least 95% identical, preferably at least 96% identical, and most preferred at least 98% identical to the nucleotide sequence of (b), (e) consisting of a nucleotide

Abstract: The present invention relates to a method for predicting whether a subject having a tumor responds to a tumor therapy selected from (i) an immunotherapy, (ii) a chemotherapy, (iii) an anti-hormonal therapy, and (iv) an anti-tyrosin kinase therapy, wherein the method comprises (A) determining the level(s) of at least one nucleic acid molecule and/or at least one protein or peptide in a sample obtained from said subject, wherein the at least one nucleic acid molecule is selected from nucleic acid molecules (a) encoding a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs 1 to 6, (b) consisting of the nucleotide sequence of any one of SEQ ID NOs 7 to 12, (c) encoding a polypeptide which is at least 85% identical, preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of (a), (d) consisting of a nucleotide sequence which is at least 95% identical, preferably at least 96% identical, and most preferred at least 98% identical to t

Abstract: The present invention relates to a nucleic acid molecule, a vector, a host cell, or a protein or peptide, or combinations thereof for use as an immunosuppressant, as a tumor vaccine or as a pregnancy promoter wherein (I) the nucleic acid molecule is (a) encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; or (b) consisting of the nucleotide sequence of SEQ ID NO: 2; or (c) encoding a polypeptide which is at least 70%, preferably at least 80% identical, more preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of SEQ ID NO: 1; or (d) consisting of a nucleotide sequence which is at least 70% identical, preferably at least 80% identical, more preferably at least 90% identical, and most preferred at least 95% identical to the nucleotide sequence of SEQ ID NO: 2; or (e) consisting of a nucleotide sequence which is degenerate with respect to the nucleic acid molecule of (d); or (f) a fragment of the nucleic acid molecule of an

Abstract: The present invention relates to a method of classifying a sample of a patient that suffers from or being at risk of developing urothelial or bladder cancer, said method comprising the steps of: a) determining in said sample from said patient, the presence or absence of alteration in an FGFR gene and/or the expression level of at least one gene encoding for a receptor selected from the group consisting of FGFR1, FGFR2, FGFR3 or FGFR4, and b) classifying the sample of said patient from the outcome of step a) into one of at least two classifications, said classifications comprising good and poor prognosis for treatment with an anti-cancer agent.

Abstract: This technology relates in part to compositions and kits comprising nucleic acids, vectors, and cells that express HLA-J, as well as HLA-J proteins and peptides, and uses thereof, for example for medical treatments, vaccines and diagnosis.

Abstract: The present invention is related to a method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining, on a non protein basis, the expression level of at least one gene of interest, said gene being correlated with the Estrogen receptor (ESR) status in the said sample, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c).

Abstract: The present invention is related to a method for analyzing a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining, on a non protein basis, the expression level of three genes of interest, said genes being correlated with the Estrogen receptor (ESR) status in the sample, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c); and treating based on said outcome.

Abstract: The present invention relates to matrix materials suitable for use in purifying and/or isolating nucleic acids from a biological sample, which matrix comprises a surface comprising at least one element selected from the group consisting of Germanium, Tin and/or Lead, or at least one salt thereof, and methods related therewith.

Abstract: The present invention relates to matrix materials suitable for use in purifying and/or isolating nucleic acids from a biological sample, which matrix comprises a surface comprising at least one element selected from the group consisting of Germanium, Tin and/or Lead, or at least one salt thereof, and methods related therewith.

Abstract: At least one embodiment of the invention relates to bone marrow precursor cells or bone marrow cells of a patient, the cells labeled with at least one contrast agent suitable for an imaging method, for use in an imaging method for diagnosing a metastasizing cancer, wherein the local accumulation of the labeled precursor cells or bone marrow cells indicates the presence of a metastasizing tumor growth. At least one embodiment also relates to a method for imaging a metastasizing tumor tissue in a patient, wherein a) bone marrow precursor cells or bone marrow cells are extracted from a patient, b) these precursor cells or bone marrow cells are labeled with at least one contrast agent suitable for an imaging method, c) the precursor cells or bone marrow cells thus labeled are retransplanted or reinjected into the patient, and d) the presence of metastasizing tumor cells is depicted with an imaging method.

Abstract: The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing cancer, preferably colorectal cancer, towards a given mode of treatment, the method including the steps of: a) obtaining a biological sample from the patient; b) determining the expression level of at least SPON-2, and optionally determining the expression level of SPON-1, in the sample; c) comparing the expression level or expression levels determined in (b) with one or several reference expression levels; and d) predicting therapeutic success for the given mode of treatment in the patient or implementing therapeutic regimen in the patient from the outcome of the comparison in step (c).

Abstract: The present invention pertains to the field of in vitro diagnostics and relates to a method for determining the risk of metastasis of a tumor, wherein a high risk of metastasis shows that subsequent examinations by means of imaging methods are indicated for the patient.

Abstract: A contrast agent is disclosed for imaging methods. In at least one embodiment the contrast agent includes a construct including i) at least two copies of a substrate for at least one tumor-specific protease, and ii) at least one linker having at least one recognition site for at least one tumor-specific protease, wherein a hyperpolarization site is located at the N and/or C terminus of the substrate, and wherein the linker is configured such that the hydrophobic ends of the substrate interact and form a central core by means of noncovalent interactions with the lipophilic residues, and the contrast agent together with a parahydrogen metal template for use in an imaging method for diagnosing a tumor.

Abstract: At least one embodiment of the invention relates to bone marrow precursor cells or bone marrow cells of a patient, the cells labeled with at least one contrast agent suitable for an imaging method, for use in an imaging method for diagnosing a metastasizing cancer, wherein the local accumulation of the labeled precursor cells or bone marrow cells indicates the presence of a metastasizing tumor growth. At least one embodiment also relates to a method for imaging a metastasizing tumor tissue in a patient, wherein a) bone marrow precursor cells or bone marrow cells are extracted from a patient, b) these precursor cells or bone marrow cells are labeled with at least one contrast agent suitable for an imaging method, c) the precursor cells or bone marrow cells thus labeled are retransplanted or reinjected into the patient, and d) the presence of metastasizing tumor cells is depicted with an imaging method.

Abstract: The present invention is related to a method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining, on a non protein basis, the expression level of at least one gene of interest, said gene being correlated with the Estrogen receptor (ESR) status in the said sample, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c). Moreover, the invention concerns nucleic acid molecules usefuls as primers and probes for detecting the expression of Her2-neu/ErbB2, MLHP and MMP7, respectively.

Abstract: The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing cancer, preferably colorectal cancer, towards a given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the expression level of at least SPON-2, and optionally determining the expression level of SPON-1, in said sample; c) comparing the expression level or expression levels determined in (b) with one or several reference expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient or implementing therapeutic regimen in said subject from the outcome of the comparison in step (C).

Abstract: The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing gynecologic cancer towards a given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the expression level of at least one gene selected from the group comprising ALCAM, Osteopontin, Her-2/neu, EGFR, uPA/PAI-1 and/or ESR1, in particular of ALCAM and/or Osteopontin, in said sample; c) comparing the pattern of expression level (s) determined in (b) with one or several reference pattern (s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient or implementing therapeutic regimen in said patient from the outcome of the comparison in step (c).

Abstract: Described are 12 human genes which are differentially expressed in neoplastic tissues of patients responding well to treatment as compared to patients not responding well as determined by overall survival time in the non responding cohort. Moreover, methods for prognosis of the therapeutic success in cancer therapy are described. These methods are based on determination of expression levels of particular genes which are differentially expressed in cancer patients, preferably the genes encoding VEGFC, ERBB3 and Her2/neu, prior to the onset of anti-cancer chemotherapy. These methods are particularly useful in the investigation of advanced head and neck cancer, but are useful in the investigation of other types of cancer and therapies as well.